Clinical Trial Update: Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088 [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of SAR445088 in adults with cold agglutinin disease, previously treated vs untreated, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Cold Agglutinin Disease

Drugs mentioned

• SAR445088

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Autoimmune Haemolytic Anaemia | Phase 1 | Status: TERMINATED